These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21763166)

  • 1. Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors.
    Wang F; Ma Z; Li Y; Zhu S; Xiao Z; Zhang H; Wang Y
    J Mol Graph Model; 2011 Sep; 30():67-81. PubMed ID: 21763166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors.
    Dhanachandra Singh Kh; Karthikeyan M; Kirubakaran P; Nagamani S
    J Mol Graph Model; 2011 Sep; 30():186-97. PubMed ID: 21831680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the structure requirement for PKCθ inhibitory activity of pyridinecarbonitrile derivatives: an in silico analysis.
    Li Y; Hao M; Ren H; Zhang S; Wang X; Ma M; Li G; Yang L
    J Mol Graph Model; 2012 Apr; 34():76-88. PubMed ID: 22306416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.
    Mascarenhas NM; Ghoshal N
    Eur J Med Chem; 2008 Dec; 43(12):2807-18. PubMed ID: 18037537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
    Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
    Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C
    J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular docking/dynamics studies of Aurora A kinase inhibitors.
    Talele TT; McLaughlin ML
    J Mol Graph Model; 2008 Jun; 26(8):1213-22. PubMed ID: 18096419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors.
    Dessalew N; Singh SK
    Med Chem; 2008 Jul; 4(4):313-21. PubMed ID: 18673142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of tricyclic piperazine/piperidine furnished molecules as novel integrin αvβ3/αIIbβ3 dual antagonists using 3D-QSAR and molecular docking.
    Yan Y; Li Y; Zhang S; Ai C
    J Mol Graph Model; 2011 Feb; 29(5):747-62. PubMed ID: 21273104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
    Ibrahim DA; El-Metwally AM
    Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational study on the interaction of N1 substituted pyrazole derivatives with B-raf kinase: an unusual water wire hydrogen-bond network and novel interactions at the entrance of the active site.
    Alzate-Morales JH; Vergara-Jaque A; Caballero J
    J Chem Inf Model; 2010 Jun; 50(6):1101-12. PubMed ID: 20524689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.